Qualigen Therapeutics, Inc. (QLGN) |
|
1.24 -0.01 (-0.8%)
|
01-27 15:59 |
|
Open: |
1.26 |
Pre. Close: |
1.25 |
|
High:
|
1.27 |
Low:
|
1.22 |
|
Volume:
|
65,051 |
Market Cap:
|
5(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:47:22 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 1.88 One year: 2.25 |
| Support: |
Support1: 1.11 Support2: 0.92 |
| Resistance: |
Resistance1: 1.61 Resistance2: 1.92 |
| Pivot: |
1.3 |
| Moving Average: |
MA(5): 1.25 MA(20): 1.31 
MA(100): 2.1 MA(250): 4.14 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 13.9 %D(3): 14.3 |
| RSI: |
RSI(14): 40.2 |
| 52-week: |
High: 15.19 Low: 0.49 |
| Average Vol(K): |
3-Month: 236 (K) 10-Days: 71 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ QLGN ] has closed above bottom band by 24.3%. Bollinger Bands are 58.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.27 - 1.28 |
1.28 - 1.28 |
|
Low:
|
1.2 - 1.21 |
1.21 - 1.22 |
|
Close:
|
1.23 - 1.24 |
1.24 - 1.25 |
|
Company Description |
|
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. |
Headline News |
Fri, 27 Jan 2023
Qualigen Therapeutics Inc (QLGN) Stock Has Fallen -2.38% This Week: Buy, Hold, or Sell? - InvestorsObserver
Wed, 18 Jan 2023
What is the Market's View on Qualigen Therapeutics Inc (QLGN) Stock's Price and Volume Trends Wednesday? - InvestorsObserver
Fri, 13 Jan 2023
Will Qualigen Therapeutics Inc (QLGN) Lag the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver
Wed, 11 Jan 2023
Premarket Mover: Qualigen Therapeutics Inc (QLGN) Down 2.99% - InvestorsObserver
Tue, 10 Jan 2023
Is Qualigen Therapeutics Inc (QLGN) Stock Worth a Buy Tuesday? - InvestorsObserver
Thu, 01 Dec 2022
QLGN: Encouraging Preclinical Data Presented for QN-302 and RAS Inhibitor… - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
4 (M) |
| Shares Float |
4 (M) |
|
% Held by Insiders
|
9 (%) |
|
% Held by Institutions
|
5.7 (%) |
|
Shares Short
|
96 (K) |
|
Shares Short P.Month
|
92 (K) |
Stock Financials |
|
EPS
|
-0.55 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.88 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-247.9 |
|
Return on Assets (ttm)
|
-40 |
|
Return on Equity (ttm)
|
-125 |
|
Qtrly Rev. Growth
|
24.7 |
|
Gross Profit (p.s.)
|
-1.15 |
|
Sales Per Share
|
1.2 |
|
EBITDA (p.s.)
|
-2.96 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-14 (M) |
|
Levered Free Cash Flow
|
-4 (M) |
Stock Valuations |
|
PE Ratio
|
-2.28 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.43 |
|
Price to Sales
|
1.02 |
|
Price to Cash Flow
|
-0.38 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-05-25 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
